Antibiotic Resistance Market Forecasts to 2030 – Global Analysis By Disease (Clostridium difficile infections, Hospital-acquired bacterial pneumonia, Complicated intra-abdominal infections, Community-acquired bacterial pneumonia, Acute bacterial skin and

Antibiotic Resistance Market Forecasts to 2030 – Global Analysis By Disease (Clostridium difficile infections, Hospital-acquired bacterial pneumonia, Complicated intra-abdominal infections, Community-acquired bacterial pneumonia, Acute bacterial skin and skin-structure infection, Bloodstream infection and Complicated urinary tract infections ), Pathogen (Baumannii, Pseudomonas aeruginosa, Enterococcus faecium, Hemophilus Influenzae, K. Pneumoniae, E. Coli, Streptococcus pneumonia, Clostridium difficile, Staphylococcus Aureus and Acinetobacter), Drug Class, Mechanism of Action, End User and By Geography.


According to Stratistics MRC, the Global Antibiotic Resistance Market is accounted for $8.75 billion in 2023 and is expected to reach $14.71 billion by 2030 growing at a CAGR of 7.7% during the forecast period. The drugs that are frequently used to treat a variety of infections are referred to as antibiotics. When bacteria endure genetic changes or mutations that allow them to live and grow even when exposed to antibiotics, antibiotic resistance develops, diminishing or completely removing the effectiveness of the drugs. As a result, infections brought on by these resistant bacteria become more challenging to treat, which causes illnesses to last longer, cost more money to treat, and may raise fatality rates.

According to the CDC, the incidence of antibiotic-resistant infections is more than 2.8 million in the U.S. The annual burden of the disease in the country is estimated between USD 21.0 billion to USD 34.0 billion. Globally, MRSA imposes a significant cost burden due to a high resistance rate of an average of 25.0% in developed countries and around 40% in developing regions.

Market Dynamics

Driver

Increasing Prevalence of Antibiotic-Resistant Infections

The increasing prevalence of antibiotic-resistant infections is a critical driver of the antibiotic resistance market. Overuse and misuse of antibiotics have led to the emergence of resistant strains of bacteria, rendering conventional antibiotics less effective. This escalating resistance poses a serious threat to public health, resulting in prolonged illnesses, increased mortality rates, and higher healthcare costs. Infections caused by antibiotic-resistant bacteria often necessitate the use of more expensive and potentially less effective second-line treatments. Consequently, there is a growing demand for innovative antibiotics and alternative therapies to combat these resistant pathogens. The need to develop new and effective antibiotics is fueling research and development efforts, attracting investments, and driving collaborations within the pharmaceutical and healthcare sectors. These factors are responsible for market growth.

Restraint

Stringent regulatory standards

The antibiotic resistance market faces stringent regulatory requirements that can pose significant challenges for drug development and market entry. Regulatory agencies demand extensive clinical trials and thorough documentation of safety and efficacy to ensure the effectiveness of new antibiotics. Meeting these requirements necessitates substantial investments of time and resources, often resulting in prolonged development timelines and increased costs. These elements are hampering market demand.

Opportunity

Development of novel antibiotics

The development of novel antibiotics presents a significant opportunity within the antibiotic resistance market. With the rise of antibiotic-resistant bacterial strains, there is an emerging need for innovative drugs that can effectively combat these resilient pathogens. Investing in the development of novel antibiotics is not only a healthcare imperative but also a promising business opportunity. Additionally, public-private partnerships and collaborations are fostering a good environment for advancing antibiotic research, encouraging innovation, and expediting the development and commercialization of new antibiotics, driven by the potential market demand for effective antibiotics and the societal impact of mitigating antibiotic resistance.

Threat

Overuse and Misuse of Antibiotics

Overuse and misuse of antibiotics constitute a significant threat to the antibiotic resistance market. Over-prescription and inappropriate use of antibiotics, often driven by patient demand, a lack of proper diagnostic tools, or medical practitioners' prescribing habits, contribute to the development of antibiotic-resistant strains. When antibiotics are used unnecessarily or incorrectly, bacteria have a higher chance of developing resistance, rendering these drugs ineffective. These factors are responsible for decreasing market growth.

Covid-19 Impact

Antibiotic use and demand increased among COVID-19 patients early in the pandemic to treat secondary bacterial infections. Antibiotic resistance may occur as a result of the increased use. Additionally, there is a better understanding of the risks associated with antibiotic resistance and the necessity for appropriate and responsible antibiotic usage as a result of the increasing awareness among the general public, healthcare professionals, and politicians. The pandemic served as a reminder of the value of antibiotic management programmes, which encourage the responsible use of antibiotics and aid in the fight against antibiotic-resistant illnesses. Healthcare systems gave priority to such initiatives to make sure that antibiotics are only given when necessary and in sufficient quantities to stop the spread of illnesses that are resistant to therapy. Overall, the pandemic had a positive impact on global market demand.

The Tetracyclines segment is expected to be the largest during the forecast period

The Tetracyclines segment is estimated to hold the largest share. This has fuelled the demand for alternative treatment options and the development of novel antibiotics. Tetracyclines, a class of antibiotics used to treat a wide range of bacterial infections, have faced challenges due to the emergence of antibiotic-resistant strains. Additionally, healthcare organisations and regulatory bodies are promoting responsible antibiotic use and implementing stringent guidelines to curb the spread of resistance. While the tetracycline’s segment has ongoing research and collaborative efforts hold promise for addressing antibiotic resistance and ensuring effective treatment options for infectious diseases.

The Hospitals & Clinics segment is expected to have the highest CAGR during the forecast period

The Hospitals & Clinics segment is anticipated to have lucrative growth during the forecast period. The hospitals and clinics segment of the antibiotic resistance market plays a crucial role in managing and combating the challenges posed by antibiotic-resistant infections. As healthcare facilities are at the forefront of diagnosing and treating patients, they face the direct impact of antibiotic resistance. This segment encompasses hospitals, clinics, and other healthcare institutions that provide medical services. Healthcare professionals in these settings are actively involved in implementing antimicrobial stewardship programmes, promoting infection prevention and control measures, and optimising the use of antibiotics. Furthermore, hospitals and clinics contribute to surveillance efforts by monitoring the prevalence and patterns of antibiotic resistance and collaborating with researchers and regulatory bodies to develop strategies for combating this global health threat.

Region with largest share

Asia Pacific commanded the largest market share during the extrapolated period due to the high prevalence of infectious diseases in the area, extensive antibiotic use has resulted. It represents the greatest user of antibiotics in the world, which raises the possibility of developing diseases with antibiotic resistance. Antibiotic-resistant bacteria have emerged and spread as a result of improper usage of antibiotics, including overuse and misuse. Additionally, the Asia-Pacific area is a hub for the propagation of resistance due to its dense population and high load of diseases that are antibiotic-resistant. The growing awareness about antibiotic resistance and the need for effective interventions are driving efforts to combat the issue in the region.

Region with highest CAGR

North America is expected to witness profitable growth over the projection period. North America region has a high prevalence of antibiotic resistance, with a significant burden of antibiotic-resistant infections reported. This is attributed to factors such as the overuse and misuse of antibiotics, both in healthcare settings and in the community. region also exhibits robust research and development activities focused on developing new antibiotics and alternative treatment options. Additionally, government initiatives and public-private partnerships in North America have played a crucial role in addressing antibiotic resistance through the implementation of antibiotic stewardship programmes and raising awareness about appropriate antibiotic use.

Key players in the market

Some of the key players in the Antibiotic Resistance Market include Basilea Pharmaceutica Ltd., Tetraphase Pharmaceuticals, Inc., Entasis therapeutics, Theravance Biopharma, Paratek Pharmaceuticals, Inc., Seres Therapeutics, Merck & Co. Inc., Achaogen Inc., Melinta Therapeutics, AbbVie, Inc., Johnson & Johnson, Pfizer Inc., Cipla Ltd., Bayer AG, AstraZeneca plc, Novartis AG, Teva Pharmaceutical Industries Ltd., Roche Holding AG, Cubist Pharmaceuticals, Inc. and Mylan N.V.

Key Developments

In June 2023, BSI, the business improvement and Standards Company, launched a new global Minimized Risk of Antimicrobial Resistance (AMR) certification designed to promote and attest to the responsible manufacturing of antibiotics in the global supply chain.

In November 2022, Quadripartite launches a new platform to tackle antimicrobial resistance threat to human and animal health and ecosystems. The Antimicrobial Resistance Multi-Stakeholder Partnership Platform was launched today to ensure the growing threats and impacts of antimicrobial resistance are addressed globally.

In November 2022, Apollo announced the launch of an Antimicrobial Stewardship Programme (Apollo ASP). The programme will sensitize care providers on Antimicrobial Resistance (AMR), an issue leading to a public health problem.

In April 2022, Johnson & Johnson announced the opening of the J&J Satellite Center for Global Health Discovery (Satellite Center) at the University of Cape Town's Holistic Drug Discovery and Development (H3D).

Diseases Covered
• Clostridium difficile infections
• Hospital-acquired bacterial pneumonia
• Complicated intra-abdominal infections
• Community-acquired bacterial pneumonia
• Acute bacterial skin and skin-structure infection
• Bloodstream infection
• Complicated urinary tract infections

Pathogens Covered
• Baumannii
• Pseudomonas aeruginosa
• Enterococcus faecium
• Hemophilus Influenzae
• K. Pneumoniae
• E. Coli
• Streptococcus pneumoniae
• Clostridium difficile
• Staphylococcus Aureus
• Acinetobacter

Drug Classes Covered
• Tetracyclines
• Cephalosporins
• Oxazolidinones
• Combination therpaies
• Lipoglycopeptides
• Other Drug Classes

Mechanism of Actions Covered
• Cell Wall Synthesis Inhibitors
• DNA Synthesis Inhibitors
• Protein Synthesis Inhibitors
• RNA synthesis inhibitors
• Other Mechanism of Actions

End Users Covered
• Hospitals & Clinics
• Homecare
• Research Organizations
• Other End Users

Regions Covered
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements


1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Antibiotic Resistance Market, By Disease
5.1 Introduction
5.2 Clostridium difficile infections
5.3 Hospital-acquired bacterial pneumonia
5.4 Complicated intra-abdominal infections
5.5 Community-acquired bacterial pneumonia
5.6 Acute bacterial skin and skin-structure infection
5.7 Bloodstream infection
5.8 Complicated urinary tract infections
6 Global Antibiotic Resistance Market, By Pathogen
6.1 Introduction
6.2 Baumannii
6.3 Pseudomonas aeruginosa
6.4 Enterococcus faecium
6.5 Hemophilus Influenzae
6.6 K. Pneumoniae
6.8 E. Coli
6.9 Streptococcus pneumoniae
6.10 Clostridium difficile
6.11 Staphylococcus Aureus
6.12 Acinetobacter
7 Global Antibiotic Resistance Market, By Drug Class
7.1 Introduction
7.2 Tetracyclines
7.3 Cephalosporins
7.4 Oxazolidinones
7.5 Combination therpaies
7.6 Lipoglycopeptides
7.7 Other Drug Classes
8 Global Antibiotic Resistance Market, By Mechanism of Action
8.1 Introduction
8.2 Cell Wall Synthesis Inhibitors
8.3 DNA Synthesis Inhibitors
8.4 Protein Synthesis Inhibitors
8.5 RNA synthesis inhibitors
8.6 Other Mechanism of ActionS
9 Global Antibiotic Resistance Market, By End User
9.1 Introduction
9.2 Hospitals & Clinics
9.3 Homecare
9.4 Research Organizations
9.5 Other End Users
10 Global Antibiotic Resistance Market, By Geography
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 Italy
10.3.4 France
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 New Zealand
10.4.6 South Korea
10.4.7 Rest of Asia Pacific
10.5 South America
10.5.1 Argentina
10.5.2 Brazil
10.5.3 Chile
10.5.4 Rest of South America
10.6 Middle East & Africa
10.6.1 Saudi Arabia
10.6.2 UAE
10.6.3 Qatar
10.6.4 South Africa
10.6.5 Rest of Middle East & Africa
11 Key Developments
11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies
12 Company Profiling
12.1 Basilea Pharmaceutica Ltd.
12.2 Tetraphase Pharmaceuticals, Inc.
12.3 Entasis therapeutics
12.4 Theravance Biopharma
12.5 Paratek Pharmaceuticals, Inc.
12.6 Seres Therapeutics
12.7 Merck & Co. Inc.
12.8 Achaogen Inc.
12.9 Melinta Therapeutics
12.10 AbbVie, Inc.
12.11 Johnson & Johnson
12.12 Pfizer Inc.
12.13 Cipla Ltd.
12.14 Bayer AG
12.15 AstraZeneca plc
12.16 Novartis AG
12.17 Teva Pharmaceutical Industries Ltd.
12.18 Roche Holding AG
12.19 Cubist Pharmaceuticals, Inc.
12.20 Mylan N.V.
List of Tables
Table 1 Global Antibiotic Resistance Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Antibiotic Resistance Market Outlook, By Disease (2021-2030) ($MN)
Table 3 Global Antibiotic Resistance Market Outlook, By Clostridium difficile infections (2021-2030) ($MN)
Table 4 Global Antibiotic Resistance Market Outlook, By Hospital-acquired bacterial pneumonia (2021-2030) ($MN)
Table 5 Global Antibiotic Resistance Market Outlook, By Complicated intra-abdominal infections (2021-2030) ($MN)
Table 6 Global Antibiotic Resistance Market Outlook, By Community-acquired bacterial pneumonia (2021-2030) ($MN)
Table 7 Global Antibiotic Resistance Market Outlook, By Acute bacterial skin and skin-structure infection (2021-2030) ($MN)
Table 8 Global Antibiotic Resistance Market Outlook, By Bloodstream infection (2021-2030) ($MN)
Table 9 Global Antibiotic Resistance Market Outlook, By Complicated urinary tract infections (2021-2030) ($MN)
Table 10 Global Antibiotic Resistance Market Outlook, By Pathogen (2021-2030) ($MN)
Table 11 Global Antibiotic Resistance Market Outlook, By Baumannii (2021-2030) ($MN)
Table 12 Global Antibiotic Resistance Market Outlook, By Pseudomonas aeruginosa (2021-2030) ($MN)
Table 13 Global Antibiotic Resistance Market Outlook, By Enterococcus faecium (2021-2030) ($MN)
Table 14 Global Antibiotic Resistance Market Outlook, By Hemophilus Influenzae (2021-2030) ($MN)
Table 15 Global Antibiotic Resistance Market Outlook, By K. Pneumoniae (2021-2030) ($MN)
Table 16 Global Antibiotic Resistance Market Outlook, By E. Coli (2021-2030) ($MN)
Table 17 Global Antibiotic Resistance Market Outlook, By Streptococcus pneumoniae (2021-2030) ($MN)
Table 18 Global Antibiotic Resistance Market Outlook, By Clostridium difficile (2021-2030) ($MN)
Table 19 Global Antibiotic Resistance Market Outlook, By Staphylococcus Aureus (2021-2030) ($MN)
Table 20 Global Antibiotic Resistance Market Outlook, By Acinetobacter (2021-2030) ($MN)
Table 21 Global Antibiotic Resistance Market Outlook, By Drug Class (2021-2030) ($MN)
Table 22 Global Antibiotic Resistance Market Outlook, By Tetracyclines (2021-2030) ($MN)
Table 23 Global Antibiotic Resistance Market Outlook, By Cephalosporins (2021-2030) ($MN)
Table 24 Global Antibiotic Resistance Market Outlook, By Oxazolidinones (2021-2030) ($MN)
Table 25 Global Antibiotic Resistance Market Outlook, By Combination therpaies (2021-2030) ($MN)
Table 26 Global Antibiotic Resistance Market Outlook, By Lipoglycopeptides (2021-2030) ($MN)
Table 27 Global Antibiotic Resistance Market Outlook, By Other Drug Classes (2021-2030) ($MN)
Table 28 Global Antibiotic Resistance Market Outlook, By Mechanism of Action (2021-2030) ($MN)
Table 29 Global Antibiotic Resistance Market Outlook, By Cell Wall Synthesis Inhibitors (2021-2030) ($MN)
Table 30 Global Antibiotic Resistance Market Outlook, By DNA Synthesis Inhibitors (2021-2030) ($MN)
Table 31 Global Antibiotic Resistance Market Outlook, By Protein Synthesis Inhibitors (2021-2030) ($MN)
Table 32 Global Antibiotic Resistance Market Outlook, By RNA synthesis inhibitors (2021-2030) ($MN)
Table 33 Global Antibiotic Resistance Market Outlook, By Other Mechanism of ActionS (2021-2030) ($MN)
Table 34 Global Antibiotic Resistance Market Outlook, By End Users (2021-2030) ($MN)
Table 35 Global Antibiotic Resistance Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
Table 36 Global Antibiotic Resistance Market Outlook, By Homecare (2021-2030) ($MN)
Table 37 Global Antibiotic Resistance Market Outlook, By Research Organizations (2021-2030) ($MN)
Table 38 Global Antibiotic Resistance Market Outlook, By Other End Users (2021-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings